

# Paola Patrignani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7860345/publications.pdf>

Version: 2024-02-01

137  
papers

9,396  
citations

41627

51  
h-index

45040

94  
g-index

138  
all docs

138  
docs citations

138  
times ranked

10447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis. <i>Cells</i> , 2022, 11, 725.	1.8	5
2	Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies. <i>Frontiers in Pharmacology</i> , 2022, 13, 838079.	1.6	20
3	Aspirin Colorectal Cancer Prevention in Lynch Syndrome: Recommendations in the Era of Precision Medicine. <i>Genes</i> , 2022, 13, 460.	1.0	7
4	Editorial: Insights in Inflammation Pharmacology: 2021. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	0
5	Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis. <i>European Journal of Medicinal Chemistry</i> , 2021, 210, 112983.	2.6	4
6	Expression and functional characterization of the large-conductance calcium and voltage-activated potassium channel Kca1.1 in megakaryocytes and platelets. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1558-1571.	1.9	4
7	Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained. <i>Pharmacological Research</i> , 2021, 170, 105744.	3.1	11
8	Editorial: Eicosanoids in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 765214.	1.6	1
9	Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase. <i>Journal of Lipid Research</i> , 2021, 62, 100109.	2.0	11
10	Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9585.	1.8	32
11	The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia. <i>Scientific Reports</i> , 2020, 10, 21420.	1.6	4
12	Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158804.	1.2	5
13	Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems. <i>Biochemical Pharmacology</i> , 2020, 178, 114094.	2.0	12
14	Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo. <i>Frontiers in Pharmacology</i> , 2020, 11, 374.	1.6	6
15	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedalscience</i> , 2020, 14, 998.	0.6	4
16	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 416-426.	1.3	18
17	miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. <i>FASEB Journal</i> , 2019, 33, 6933-6947.	0.2	30
18	Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. <i>Frontiers in Pharmacology</i> , 2019, 10, 7.	1.6	44

#	ARTICLE	IF	CITATIONS
19	Reduced Variability to Aspirin Antiplatelet Effect by the Coadministration of Statins in High-Risk Patients for Cardiovascular Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 111-119.	2.3	7
20	Platelets in cancer development and diagnosis. <i>Biochemical Society Transactions</i> , 2018, 46, 1517-1527.	1.6	33
21	Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 455-467.	2.7	45
22	P2Y12 Receptors in Tumorigenesis and Metastasis. <i>Frontiers in Pharmacology</i> , 2018, 9, 66.	1.6	48
23	Antithrombotic Agents and Cancer. <i>Cancers</i> , 2018, 10, 253.	1.7	28
24	Aspirin, platelet inhibition and cancer prevention. <i>Platelets</i> , 2018, 29, 779-785.	1.1	58
25	Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 52-61.	2.3	38
26	Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. <i>Vascular Pharmacology</i> , 2017, 89, 1-11.	1.0	20
27	Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3491-3507.	2.4	60
28	Nonsteroidal anti-inflammatory drugs and cardiovascular safety – translating pharmacological data into clinical readouts. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 791-807.	1.0	50
29	Therapeutic targeting of dysregulated cellular communication. <i>Annals of Translational Medicine</i> , 2017, 5, 222-222.	0.7	1
30	Time for Integrating Clinical, Lifestyle and Molecular Data to Predict Drug Responses. <i>EBioMedicine</i> , 2016, 7, 9-10.	2.7	2
31	Molecular and Experimental Basis for COX Inhibition in Cancer. , 2016, , 175-201.		0
32	Aspirin and Cancer. <i>Journal of the American College of Cardiology</i> , 2016, 68, 967-976.	1.2	209
33	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. <i>Oncotarget</i> , 2016, 7, 32462-32477.	0.8	130
34	Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. <i>Biochemical Society Transactions</i> , 2015, 43, 707-714.	1.6	29
35	MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer. <i>Oncotarget</i> , 2015, 6, 10284-10296.	0.8	48
36	Aspirin in the 21st century – common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK. <i>Ecancermedalscience</i> , 2015, 9, 581.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F <sub>2</sub> Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1687-1695.	1.1	15
38	Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. <i>Drugs</i> , 2015, 75, 859-877.	4.9	284
39	New insights into the use of currently available non-steroidal anti-inflammatory drugs. <i>Journal of Pain Research</i> , 2015, 8, 105.	0.8	291
40	Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF- $\beta$ 1. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 103-114.	1.0	10
41	Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells. <i>British Journal of Pharmacology</i> , 2015, 172, 4575-4587.	2.7	16
42	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015, 1851, 422-432.	1.2	169
43	New Insights into the Mechanism of Action of Aspirin in the Prevention of Colorectal Neoplasia. <i>Current Pharmaceutical Design</i> , 2015, 21, 5116-5126.	0.9	21
44	Inside epoxyeicosatrienoic acids and cardiovascular disease. <i>Frontiers in Pharmacology</i> , 2014, 5, 239.	1.6	42
45	Role of Platelets in Inflammation and Cancer: Novel Therapeutic Strategies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 118-127.	1.2	72
46	Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 56-63.	1.2	85
47	Gut Microbiota, Host Gene Expression, and Aging. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S28-S31.	1.1	35
48	Platelets, Cyclooxygenases, and Colon Cancer. <i>Seminars in Oncology</i> , 2014, 41, 385-396.	0.8	37
49	Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1320-1330.	1.9	79
50	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 772-786.	1.4	25
51	Pharmacological Inhibition of Platelet-Tumor Cell Cross-Talk Prevents Platelet-Induced Overexpression of Cyclooxygenase-2 in HT29 Human Colon Carcinoma Cells. <i>Molecular Pharmacology</i> , 2013, 84, 25-40.	1.0	98
52	In Vitro morphine metabolism by rat microglia. <i>Neuropharmacology</i> , 2013, 75, 391-398.	2.0	16
53	A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3695-3701.	1.4	74
54	Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 3191-3206.	2.9	43

#	ARTICLE	IF	CITATIONS
55	Mode of Action of Aspirin as a Chemopreventive Agent. <i>Recent Results in Cancer Research</i> , 2013, 191, 39-65.	1.8	105
56	Synthesis, Pharmacological Characterization, and Docking Analysis of a Novel Family of Diarylisoxazoles as Highly Selective Cyclooxygenase-1 (COX-1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4277-4299.	2.9	88
57	Coxibs: Pharmacology, Toxicity and Efficacy in Cancer Clinical Trials. <i>Recent Results in Cancer Research</i> , 2013, 191, 67-93.	1.8	38
58	Lipid Peroxidation and Depressed Mood in Community-Dwelling Older Men and Women. <i>PLoS ONE</i> , 2013, 8, e65406.	1.1	32
59	Mechanistic Aspects of COX-2 Expression in Colorectal Neoplasia. <i>Recent Results in Cancer Research</i> , 2013, 191, 7-37.	1.8	79
60	Oxidative Damage, Platelet Activation, and Inflammation to Predict Mobility Disability and Mortality in Older Persons: Results From the Health Aging and Body Composition Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67A, 671-676.	1.7	63
61	Effects of Celecoxib on Prostanoid Biosynthesis and Circulating Angiogenesis Proteins in Familial Adenomatous Polyposis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 242-250.	1.3	31
62	Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, e1-e13.	1.0	25
63	Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cyclooxygenase-2 isoenzyme. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 287-298.	2.6	16
64	Mechanistic and Pharmacological Issues of Aspirin as an Anticancer Agent. <i>Pharmaceuticals</i> , 2012, 5, 1346-1371.	1.7	64
65	Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. <i>Prostaglandins and Other Lipid Mediators</i> , 2012, 98, 122-128.	1.0	11
66	Novel Analgesic/Anti-Inflammatory Agents: Diarylpyrrole Acetic Esters Endowed with Nitric Oxide Releasing Properties. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 7759-7771.	2.9	42
67	Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: Recommendations to minimize the functional consequences. <i>Arthritis and Rheumatism</i> , 2011, 63, 850-859.	6.7	56
68	Managing the adverse effects of nonsteroidal anti-inflammatory drugs. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 605-621.	1.3	82
69	Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. <i>Journal of Clinical Investigation</i> , 2011, 121, 4462-4476.	3.9	95
70	Novel Ester and Acid Derivatives of the 1,5-Diarylpyrrole Scaffold as Anti-Inflammatory and Analgesic Agents. Synthesis and in Vitro and in Vivo Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 723-733.	2.9	43
71	Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2010, 105, 1102-1106.	0.7	38
72	Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. <i>Biochemical Pharmacology</i> , 2010, 79, 974-981.	2.0	49

#	ARTICLE	IF	CITATIONS
73	Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. <i>Arthritis and Rheumatism</i> , 2010, 62, 1592-1601.	6.7	204
74	Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. <i>Frontiers in Pharmacology</i> , 2010, 1, 2.	1.6	0
75	NCX 4040, a Nitric Oxide-Donating Aspirin, Exerts Anti-Inflammatory Effects through Inhibition of $\text{Î}^\text{B}$ - $\text{Î}^\text{Î}$ Degradation in Human Monocytes. <i>Journal of Immunology</i> , 2010, 184, 2140-2147.	0.4	20
76	NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. <i>Pharmacological Reports</i> , 2010, 62, 530-535.	1.5	41
77	Measurement of 8-Iso-Prostaglandin $\text{F}_2^\text{Î}$ in Biological Fluids as a Measure of Lipid Peroxidation. <i>Methods in Molecular Biology</i> , 2010, 644, 165-178.	0.4	22
78	Extraction and Measurement of Prostanoids and Isoprostanes: Introduction to Part II. <i>Methods in Molecular Biology</i> , 2010, 644, 147-152.	0.4	0
79	T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. <i>Neuropharmacology</i> , 2009, 56, 637-646.	2.0	29
80	Induction of Prostacyclin by Steady Laminar Shear Stress Suppresses Tumor Necrosis Factor- $\text{Î}$ Biosynthesis via Heme Oxygenase-1 in Human Endothelial Cells. <i>Circulation Research</i> , 2009, 104, 506-513.	2.0	85
81	Synthesis, in vitro, and in vivo biological evaluation and molecular docking simulations of chiral alcohol and ether derivatives of the 1,5-diarylpyrrole scaffold as novel anti-inflammatory and analgesic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8072-8081.	1.4	18
82	Role of Dose Potency in the Prediction of Risk of Myocardial Infarction Associated With Nonsteroidal Anti-Inflammatory Drugs in the General Population. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1628-1636.	1.2	271
83	Synthesis, Biological Evaluation, and Enzyme Docking Simulations of 1,5-Diarylpyrrole-3-Alkoxyethyl Ethers as Selective Cyclooxygenase-2 Inhibitors Endowed with Anti-inflammatory and Antinociceptive Activity. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 4476-4481.	2.9	50
84	Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 29-42.	1.0	8
85	Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease. <i>Hypertension</i> , 2008, 51, 1379-1385.	1.3	82
86	Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 611-620.	0.7	33
87	Risk management profile of etoricoxib: an example of personalized medicine. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 983-997.	0.9	18
88	NSAIDs and cardiovascular disease. <i>Heart</i> , 2007, 94, 395-397.	1.2	18
89	EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. <i>FASEB Journal</i> , 2007, 21, 2418-2430.	0.2	86
90	Cyclooxygenase-2 Inhibitors. 1,5-Diarylpyrrol-3-acetic Esters with Enhanced Inhibitory Activity toward Cyclooxygenase-2 and Improved Cyclooxygenase-2/Cyclooxygenase-1 Selectivity. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5403-5411.	2.9	56

#	ARTICLE	IF	CITATIONS
91	Human Pharmacology of Naproxen Sodium. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 322, 453-460.	1.3	64
92	Pharmacodynamic of cyclooxygenase inhibitors in humans. <i>Prostaglandins and Other Lipid Mediators</i> , 2007, 82, 85-94.	1.0	165
93	The ever growing story of cyclo-oxygenase inhibition. <i>Lancet, The</i> , 2006, 368, 1745-1747.	6.3	30
94	Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. <i>Blood</i> , 2006, 107, 3572-3574.	0.6	36
95	Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 115-125.	2.3	27
96	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 264-274.	2.3	103
97	Homeodomain-Interacting Protein Kinase-2 Restrains Cytosolic Phospholipase A2-Dependent Prostaglandin E2 Generation in Human Colorectal Cancer Cells. <i>Clinical Cancer Research</i> , 2006, 12, 735-741.	3.2	50
98	De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin. <i>Circulation Research</i> , 2006, 98, 593-595.	2.0	122
99	Clinical pharmacology of etoricoxib. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 269-282.	1.5	15
100	Isoprostanes and other markers of peroxidation in atherosclerosis. <i>Biomarkers</i> , 2005, 10, 24-29.	0.9	39
101	New insights into COX-2 biology and inhibition. <i>Brain Research Reviews</i> , 2005, 48, 352-359.	9.1	105
102	Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1295-1301.	1.2	252
103	The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. <i>Pharmacological Reports</i> , 2005, 57 Suppl, 66-85.	1.5	10
104	Clinical Pharmacology of Novel Selective COX-2 Inhibitors. <i>Current Pharmaceutical Design</i> , 2004, 10, 589-601.	0.9	62
105	Clinical Pharmacology of Platelet, Monocyte, and Vascular Cyclooxygenase Inhibition by Naproxen and Low-Dose Aspirin in Healthy Subjects. <i>Circulation</i> , 2004, 109, 1468-1471.	1.6	224
106	Determinants of Platelet Activation in Human Essential Hypertension. <i>Hypertension</i> , 2004, 43, 64-70.	1.3	80
107	Novel Synthesis of 3,4-Diarylisoxazole Analogues of Valdecoxib: Reversal Cyclooxygenase-2 Selectivity by Sulfonamide Group Removal. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 4881-4890.	2.9	67
108	Lumiracoxib. <i>Drugs</i> , 2004, 64, 2247-2248.	4.9	4

#	ARTICLE	IF	CITATIONS
109	Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. <i>British Journal of Pharmacology</i> , 2003, 138, 634-641.	2.7	41
110	Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. <i>Thrombosis Research</i> , 2003, 110, 281-286.	0.8	62
111	Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 265-284.	0.9	44
112	Modulation of Aspirin-Insensitive Eicosanoid Biosynthesis by 6-Methylprednisolone in Unstable Angina. <i>Circulation</i> , 2003, 107, 55-61.	1.6	30
113	Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2003, 4, 265-284.	0.9	41
114	The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme Activity. <i>Current Medical Research and Opinion</i> , 2002, 18, 503-511.	0.9	82
115	Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease. <i>Circulation</i> , 2002, 106, 2800-2805.	1.6	199
116	Amplification loops: thromboxane generation. , 2002, , 369-380.		2
117	The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 415-424.	2.3	0
118	The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 475-483.	2.3	35
119	Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. <i>Journal of Clinical Investigation</i> , 2001, 108, 7-13.	3.9	361
120	Effects of Vitamin E Supplementation on F <sub>2</sub> -Isoprostane and Thromboxane Biosynthesis in Healthy Cigarette Smokers. <i>Circulation</i> , 2000, 102, 539-545.	1.6	106
121	Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina. <i>Circulation</i> , 2000, 102, 1007-1013.	1.6	212
122	Nonsteroidal anti-inflammatory drugs, COX-2 and colorectal cancer. <i>Toxicology Letters</i> , 2000, 112-113, 493-498.	0.4	32
123	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 63, 672-681.	2.3	47
124	Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina. <i>Circulation</i> , 1997, 96, 1109-1116.	1.6	133
125	Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclooxygenase-dependent F <sub>2</sub> -isoprostane formation. <i>British Journal of Pharmacology</i> , 1996, 118, 1285-1293.	2.7	76
126	Effects of nabumetone on prostanoid biosynthesis in humans*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 335-341.	2.3	35



#	ARTICLE	IF	CITATIONS
127	Effects of the novel anti-inflammatory compounds, Nâ€{2â€(cyclohexyloxy)â€4â€nitrophenyl]methanesulphonamide (NSâ€398) and 5â€methanesulphonamidoâ€6â€(2, 4â€difluorothiophenyl)â€1â€indanone. (Lâ€745,)Tj ETQq Journal of Pharmacology, 1995, 116, 2429-2434.	2.7	77
128	Improvement of Renal Function with Selective Thromboxane Antagonism in Lupus Nephritis. New England Journal of Medicine, 1989, 320, 421-425.	13.9	118
129	Clinical pharmacology of platelet cyclooxygenase inhibition.. Circulation, 1985, 72, 1177-1184.	1.6	424
130	Physiologic variables affecting thromboxane B2 production in human whole blood. Thrombosis Research, 1985, 37, 1-8.	0.8	44
131	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. American Journal of Cardiology, 1985, 55, 589-590.	0.7	32
132	Release of two vasodilators, adenosine and prostacyclin, from isolated rabbit hearts during controlled hypoxia.. Journal of Physiology, 1983, 340, 487-501.	1.3	67
133	Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT. Journal of Clinical Investigation, 1983, 71, 762-768.	3.9	153
134	Evidence for a Direct Stimulatory Effect of Prostacyclin on Renin Release in Man. Journal of Clinical Investigation, 1982, 69, 231-239.	3.9	196
135	Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy Subjects. Journal of Clinical Investigation, 1982, 69, 1366-1372.	3.9	854
136	Pharmaceutical Exploitation: Cyclooxygenase and Lipoxygenase Inhibitors. , 0, , 599-612.		0
137	Editorial: Women in Inflammation Pharmacology: 2021. Frontiers in Pharmacology, 0, 13, .	1.6	0